Global Human Leukocyte Antigen (HLA) Typing for Transplant Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Global Human Leukocyte Antigen (HLA) Typing for Transplant Market Segmentation, By Products and Services (Reagents and Consumables, Instruments, and Software and Services), Technology (Molecular Assay Technologies and Non- Molecular Assay Technologies), Transplant Type (Solid Organ Transplant and Hematopoietic Stem Cell Transplant), Application (Diagnostic Applications and Research Application), End User (Independent Reference Laboratories, Hospitals and Transplant Centers, and Research Laboratories and Academic Institutes)  - Industry Trends and Forecast to 2032

 Human Leukocyte Antigen (HLA) Typing for Transplant Market Size    

• The global human leukocyte antigen (HLA) typing for transplant market size was valued at USD 991.23 billion in 2024 and is expected to reach USD 1889.77 billion by 2032, at a CAGR of 8.40% during the forecast period
• This growth is driven by factors such as the rising number of organ transplants, increasing prevalence of chronic and autoimmune diseases, advancements in molecular diagnostic technologies

Human Leukocyte Antigen (HLA) Typing for Transplant Market Analysis

• Human leukocyte antigen (HLA) typing determines if patients and donors are compatible for cord blood or bone marrow transplants. Human leukocyte antigens (HLA) are proteins found in our bodies
• The human immune system uses these markers to determine which cells belong in your body and which cells are foreign
• North America is expected to dominate the Human Leukocyte Antigen (HLA) Typing for Transplants market due to advanced healthcare infrastructure, and substantial investments in transplant technologies
• Asia-Pacific is expected to be the fastest growing region in the Human Leukocyte Antigen (HLA) Typing for Transplant market during the forecast period due to increasing healthcare expenditure and improving healthcare infrastructure
• Reagents and consumables segment is expected to dominate the market with a market share due to every HLA typing test requires multiple reagents and consumables, including primers, probes, PCR reagents, buffers, and other materials

Report Scope and Human Leukocyte Antigen (HLA) Typing for Transplant Market Segmentation

Human Leukocyte Antigen (HLA) Typing for Transplant Market Trends

“Integration of Next-Generation Sequencing (NGS) and Artificial Intelligence (AI) in HLA Typing”

• The HLA typing market is experiencing a significant shift towards the adoption of Next-Generation Sequencing (NGS) technologies, offering high-resolution genotyping and comprehensive analysis of HLA alleles
• NGS enables precise matching between organ donors and recipients, enhancing transplant success rates and reducing the risk of rejection
• Artificial Intelligence (AI) and machine learning algorithms are being integrated into HLA typing processes to automate data analysis, interpret complex genetic information, and predict transplant outcomes more accurately
• These technological advancements are streamlining the HLA typing workflow, reducing turnaround times, and improving the overall efficiency of transplant procedures
• The combination of NGS and AI is expected to drive the market's growth by providing more accurate, cost-effective, and timely solutions for HLA typing in transplant medicine

Human Leukocyte Antigen (HLA) Typing for Transplant Market Dynamics

Driver

“Increasing Demand for Organ Transplants”

• The global prevalence of chronic diseases such as end-stage renal disease, liver cirrhosis, and certain cancers is rising, leading to a higher demand for organ transplants
• The aging population worldwide is contributing to an increased incidence of organ failure, further escalating the demand for transplantation procedures
• Advancements in surgical techniques and post-transplant care have improved transplant success rates, encouraging more patients to consider organ transplantation as a viable treatment option
• As the number of transplant procedures rises, the necessity for accurate HLA typing to ensure compatibility between donors and recipients becomes more critical, driving the market's growth

Opportunity

“Expansion of Organ Donation Programs and Awareness Initiatives”

• Governments and non-governmental organizations are launching campaigns to raise awareness about the importance of organ donation, aiming to increase donor registration and reduce transplant waiting times
• Countries such as the United States and Germany have established robust organ procurement systems, facilitating a steady supply of organs for transplantation
• Emerging economies in Asia-Pacific and Latin America are improving healthcare infrastructure and implementing organ donation programs, expanding the potential donor pool
• Collaborations between transplant centers, research institutions, and biotechnology companies are fostering innovation in HLA typing technologies, enhancing the accuracy and efficiency of donor-recipient matching
• The growth of organ donation programs and increased public awareness are expected to lead to a higher number of transplant procedures, thereby boosting the demand for HLA typing services

Restraint/Challenge

“High Cost of Advanced HLA Typing Technologies”

• Next-Generation Sequencing (NGS) and Polymerase Chain Reaction (PCR)-based HLA typing methods are associated with high operational costs, including expensive reagents, equipment, and maintenance
• In regions such as India, the cost of HLA typing tests can range depending on the test's complexity and resolution, posing financial challenges for patients and healthcare providers
• Limited reimbursement policies for HLA typing procedures in certain countries further exacerbate the financial burden, restricting access to advanced typing technologies
• The high cost of HLA typing technologies may hinder widespread adoption, particularly in low-resource settings, potentially impacting the overall growth of the transplant market

Human Leukocyte Antigen (HLA) Typing for Transplant Market Scope

The market is segmented on the basis of products and services, technology, transplant type, application, and end user.

In 2025, the reagents and consumables is projected to dominate the market with a largest share in product and services segment

The reagents and consumables segment is expected to dominate the Human Leukocyte Antigen (HLA) Typing for transplant market with the largest share in 2025 due to Every HLA typing test requires multiple reagents and consumables, including primers, probes, PCR reagents, buffers, and other materials. The recurring nature of their use ensures a continuous demand for these products

The molecular assay technologies is expected to account for the largest share during the forecast period in technology segment

In 2025, the molecular assay technologies segment is expected to dominate the market with the largest market share due to these technologies offer higher precision and accuracy in HLA typing. They allow for detailed analysis of HLA alleles at the DNA level, resulting in more reliable compatibility assessments

Human Leukocyte Antigen (HLA) Typing for Transplant Market Regional Analysis

“North America Holds the Largest Share in the Human Leukocyte Antigen (HLA) Typing for Transplant Market”

• North America is the leading region in the Global HLA Typing for Transplant Market
• The U.S. is a major contributor, driven by a high number of transplant procedures, advanced healthcare infrastructure, and substantial investments in transplant technologies
• Favorable reimbursement policies and a well-established organ donation system further support market growth in this region 
• The presence of leading diagnostic companies and research institutions enhances the adoption of advanced HLA typing technologies
• North America's dominance is also attributed to its robust regulatory framework and high awareness about organ transplantation

“Asia-Pacific is Projected to Register the Highest CAGR in the Human Leukocyte Antigen (HLA) Typing for Transplant Market”

• Asia-Pacific is the fastest-growing region in the Global HLA Typing for Transplant Market
• Countries such as China, India, and Japan are witnessing rapid market expansion due to increasing healthcare expenditure and improving healthcare infrastructure
• Rising awareness about organ donation and transplantation, along with government initiatives, contribute to the growing demand for HLA typing services
• The region's large patient population and expanding biotechnology sector create significant market opportunities 
• Despite challenges such as regulatory compliance and limited awareness in certain areas, the Asia-Pacific region is expected to continue its rapid growth trajectory

Human Leukocyte Antigen (HLA) Typing for Transplant Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• Thermo Fisher Scientific (U.S.)
• QIAGEN (Netherlands)
• Illumina (U.S.)
• CareDx, (U.S.)
• Immucor, (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• F. Hoffman-La Roche Ltd. (Switzerland)
• Hologic, Inc. (U.S.)
• Luminex Corporation (U.S)
• Biofortuna (U.K.)
• Bruker (U.S.)
• Abbott (U.S.)
• Takara Bio Inc.,(Japan)
• Omixon Inc., (Hungary)
• Siemens (Germany)
• EKF Diagnostics (U.K.)
• BD (U.S.)
• Fujirebio, (Japan)
• TBG Diagnostics Limited (Australia)

Latest Developments in Global Human Leukocyte Antigen (HLA) Typing for Transplant Market

• In September 2023, Omixon, Inc. introduced the NanoTYPE RUO Multiplex Human Leukocyte Antigen Amplification kit, which is compatible with the Oxford Nanopore’s MinION Platform. This product aims to enhance the efficiency of HLA typing procedures.
• In November 2022, Illumina, Inc. opened a new Solutions Center in Dubai, aimed at expanding genomics research capabilities in the Middle East.
• In March 2022, Immucor, Inc. launched the MIA FORA NGS Express HLA Typing Software, which is designed to improve the accuracy and speed of HLA typing processes.
• In May 2022, Mylab Discovery Solutions launched DiscoverSeries HLAB*27 detection kit, an in-vitro diagnostic test for Ankylosing Spondylitis (AS).
• In April 2022, Genome Diagnostics (GenDx), a Dutch molecular diagnostics firm received approval from Canadian regulators for the invitro diagnostic use of its NGSgo-MX11-3 human leukocyte antigen genotyping test.     

SKU-13067